Respiratory drugmaker Beyond Air Q2 net loss misses estimates

Beyond Air

10/11/2025 21:29

Overview

Beyond Air fiscal Q2 revenue rises 128% YoY to $1.8 mln, driven by LungFit PH demand

Net loss and operating loss for Q2 missed analyst expectations

Company updates fiscal 2026 revenue guidance to $8-$10 mln

Outlook

Beyond Air updates fiscal 2026 revenue guidance to $8-10 mln

Company anticipates FDA approval of second-gen LungFit PH by end of 2026

Recent capital infusion to support commercial and regulatory initiatives

Result Drivers

LUNGFIT PH DEMAND - Revenue growth driven by increased demand for LungFit PH in the U.S.

GLOBAL EXPANSION - International revenue growth supported by new distribution agreements in multiple countries

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$1.25
Q2 Net Income
Miss
-$8.26 mln
-$6.80 mln (4 Analysts)
Q2 Operating Income
Miss
-$7.66 mln
-$7 mln (4 Analysts)
Q2 Gross Profit
-$298,000
Q2 Operating Expenses
-$7.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Beyond Air Inc is $11.50, about 84.7% above its November 7 closing price of $1.76

Press Release: ID:nGNXbLsGh7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)